Our Science
Cutting-edge research and technology
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Go beyond your past, make a positive change

Why invest in PMI?

We've built the world's most successful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 7296

4.02 (5.83%)

Investor Relations

Latest News & Press Releases

Media Center
  • News 09 Jul, 2020

    The perfect match: Seven tips for building your dream team

  • Press Release 07 Jul, 2020

    FDA Authorizes Marketing of IQOS as a Modified Risk Tobacco Product

  • News 06 Jul, 2020

    The U.S. FDA authorizes PMI’s IQOS as a modified risk tobacco product

  • Press Release 30 Jun, 2020

    PMI Reports 2019 ESG Performance in Its First Integrated Report

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOS in the U.S. as a modified risk product are currently under review.